Key Details
Price
$56.70Last Dividend
$0.62Annual Revenue
$45.01 BAnnual EPS
$3.86Annual ROE
26.48%Beta
0.12Events Calendar
Next earnings date:
Feb 06, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 02, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Jan 03, 2025Next split:
N/ARecent split:
Aug 07, 2001Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Bristol Myers Squibb (BMY) finished the last trading day at $56.59, which is a decrease of 0.35% compared to the day before.
Bristol Myers (BMY) has been getting a lot of interest from users on Zacks.com recently. As a result, it's important to understand the factors that could affect the stock's future.
The healthcare industry has been a safe haven for income investors looking for stability and growth for a long time. In this field, Bristol-Myers Squibb (BMY -2.81%) and Merck & Co. (MRK -1.33%) are notable for their high dividend yields and reliable business strategies.
Bristol-Myers Squibb's stock appears to be undervalued, and the second half of 2024 is expected to be strong, especially with the anticipated approval of Opdivo in its subcutaneous form.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--The US FDA has given the green light for Opdivo Qvantig Injection to be used under the skin for most of the adult solid tumor indications that were previously approved for Opdivo.
On Friday, the U.S. Food and Drug Administration announced that it has given approval for an injectable form of Opdivo, a highly successful cancer treatment from Bristol Myers Squibb.
The European Commission has given the green light for Bristol Myers' Opdivo combined with Yervoy to be used as the first-line treatment for patients with MSI-H or dMMR unresectable or metastatic colorectal cancer.
BMY's stock price performed well in the first half of 2024, supported by a market shift in July and August and the US FDA's quick approval of its new schizophrenia treatment. This success follows the addition of eight new oncology trials over the past year, as the company aims to find new growth opportunities despite facing patent expirations. These factors have contributed to a 20% year-on-year increase in BMY's Growth portfolio, which now makes up 48.7% of its overall portfolio.
Bristol Myers Squibb (BMY) finished the last trading day at $56.30, which is a decrease of 0.95% compared to the day before.
If you're retired and looking for a reliable source of income, high-yield dividend stocks can be a great way to maximize your funds. Although the typical stock in the S&P 500 offers an average return of only 1.2%, there are plenty of other stocks that provide much higher returns without being too risky for your investment portfolio.
FAQ
- What is the primary business of Bristol-Myers Squibb?
- What is the ticker symbol for Bristol-Myers Squibb?
- Does Bristol-Myers Squibb pay dividends?
- What sector is Bristol-Myers Squibb in?
- What industry is Bristol-Myers Squibb in?
- What country is Bristol-Myers Squibb based in?
- When did Bristol-Myers Squibb go public?
- Is Bristol-Myers Squibb in the S&P 500?
- Is Bristol-Myers Squibb in the NASDAQ 100?
- Is Bristol-Myers Squibb in the Dow Jones?
- When was Bristol-Myers Squibb's last earnings report?
- When does Bristol-Myers Squibb report earnings?
- Should I buy Bristol-Myers Squibb stock now?